Scott Henry

ROTH Capital Partners

Image: Scott Henry

Scott Henry is the head of healthcare research and a senior research analyst with ROTH Capital Partners, covering the specialty pharmaceutical sector. He came to ROTH Capital from OppenheimerFunds, where he led coverage of the U.S. pharmaceutical sector. He has also been affiliated with Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. His coverage universe has included specialty pharmaceuticals, large-cap pharmaceuticals, biotech and selective medical device names. He has 12 years of sellside experience. Henry was ranked #2 in The Wall Street Journal's "Best on the Street" stock-picking survey in 2010 and #3 on the Forbes/Zacks Investment Research "Best Analysts" list for the Drugs category in 2010. His investment views have been cited in The Wall Street Journal and The New York Times and he has made frequent appearances on CNBC, CBS Marketwatch, and Bloomberg. Henry attended the University of Rhode Island and received a master's degree in business administration with distinction from Cornell University.

Recent Articles

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co. 08/29/2023

Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.

Med Tech Firm's Q2/23 Revenue Beats Target 08/10/2023

The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report.

Recent Quotes

"CRMD reported earnings within the range of expectations."

— Scott Henry, ROTH Capital Partners (11/16/15)
more >

Due to permission requirements, not all quotes are shown.